Medical technology company Implanet announces it has received regulatory clearance—510(k) in the US and CE Mark in Europe—to market the Jazz Claw hybrid implant.
The Jazz Claw, designed to treat degenerative pathologies in adults (kyphosis), provides autostable posterior fixation in place of traditional hook-and-screw fixation systems.
Along with the treatment of adult degenerative deformities, another use for the Jazz Claw is to help aid in the treatment of scoliosis with hybrid fixation, according to a release from Implanet, which is based in France and has its US headquarters in Boston.
“Jazz Claw is Implanet’s response to the complex issue of securing the top of constructs in adolescent scoliosis and adult degenerative deformities. This biomechanically challenging area was traditionally treated with pedicle screws or hooks, with inherent drawbacks that the Jazz Claw eliminates,” says Régis Le Couedic, Implanet’s product development & manufacturing director, in the release.
“Jazz Claw is a major new component of our Jazz Band platform, an implant that supplements our product offering for major deformities and meets a major market demand,” adds Ludovic Lastennet, CEO of Implanet, in the release.
For more information, visit Implanet.
[Source(s): Implanet, Business Wire]